Tissue plasminogen activator

Phase 3Small molecule

NNeuroscience Trials Australia

Tissue plasminogen activator is one of 102 small molecule programs targeting Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemorrhageActive, not recruiting

ThromboembolismActive, not recruiting

TrialRecruiting

Tissue Plasminogen ActivatorEnrolling by invitation

HemorrhagePreclinical

Active, not recruiting

ThromboembolismPreclinical

Active, not recruiting

TrialPreclinical

Recruiting

Tissue Plasminogen ActivatorPhase 3

Enrolling by invitation

Competition

Competitive Landscape

133 competitors in Trial

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

4 2

Herceptin

Roche

Phase 3

4 3

Yervoy

Bristol-Myers Squibb

Phase 3

3 4

Camptosar

Pfizer

Phase 3

2 5

Eloxatin

Teva

Phase 3

2 6

Vectibix

Amgen

Phase 3

2 7

Perjeta

Roche

Phase 3

2 8

Tarceva

OOSI Pharmaceuticals

Phase 3

5 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 10

Adrucil

EElorac, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stroke5 trials

Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Completed·MMelbourne Health·Phase 2·NCT04071613·104 enrolled

Regisry of the Stroke Patients in Assiut University Hospital

Unknown status·—·N/A·NCT03392792·1 enrolled

A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA

Unknown status·DD-Pharm Ltd.·Phase 2·NCT02572336·40 enrolled

Show 2 more trials

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429476·234 enrolled

Thrombolysis in Pediatric Stroke (TIPS)

Terminated·SSeattle Children's Hospital·Phase 1·NCT01591096·1 enrolled

Ischemic stroke3 trials

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

Completed·UUniversity of California, San Diego·Phase 1·NCT00283088·130 enrolled

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Completed·NNeuroscience Trials Australia·Phase 2·NCT02388061·202 enrolled

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

Terminated·UUniversity of Virginia·Phase 2·NCT00252239·112 enrolled

Subarachnoid Hemorrhage2 trials

Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage

Unknown status·UUniversity of Calgary·Phase 2·NCT01098890·12 enrolled

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

Withdrawn·RRush University Medical Center·Phase 1/2·NCT01878136

Thrombolysis2 trials

Extending the Time for Thrombolysis in Emergency Neurological Deficits

Completed·NNeuroscience Trials Australia·Phase 3·NCT00887328·180 enrolled

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Completed·NNeuroscience Trials Australia·Phase 3·NCT01580839·45 enrolled

Myocardial Infarction2 trials

Thrombolysis in Myocardial Infarction (TIMI)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000505

Myocardial Infarction Triage and Intervention Project (MITI)

Completed·UUniversity of Washington·Phase 3·NCT00000468

14 more indications

STEMI1 trial

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Completed·PPopulation Health Research Institute·Phase 3·NCT03335839·210 enrolled

Myocardial Ischemia1 trial

Thrombolysis in Myocardial Ischemia Trial (TIMI III)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000472

Hematoma1 trial

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Completed·HHamilton Health Sciences Corporation·Phase 4·NCT05491356·40 enrolled

Retinal Vein Occlusion1 trial

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01581411·1 enrolled

Prosthetic Valve Thrombosis1 trial

Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

Completed·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT01451320·182 enrolled

CAR1 trial

Thrombolytic Care During Inter-hospital Transfer

Completed·UUniversity of Iowa··NCT02752256·76 enrolled

Fibrinolysis1 trial

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

Suspended·—··NCT06310018·60 enrolled

Hemorrhage1 trial

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05736757·20 enrolled

Abdominal Abscess1 trial

Safety and Effectiveness of tPA in Intra-abdominal Abscesses

Terminated·UUniversity Health Network, Toronto·Phase 2/3·NCT00417768·35 enrolled

Peritonitis1 trial

The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients

Terminated·SSir Charles Gairdner Hospital·Phase 1·NCT01478698·5 enrolled

Thromboembolism1 trial

Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

Unknown status·—··NCT05512702·100 enrolled

Acute Respiratory Distress Syndrome1 trial

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Withdrawn·NNegovsky Reanimatology Research Institute·Phase 3·NCT04453371

Pleural Infection1 trial

A Pilot Study Comparing the Clinical Efficacy and Bleeding Risk Between Low Dose and Standard Dose Intrapleural Tissue Plasminogen Activator for Pleural Infection

Completed·CChinese University of Hong Kong·Preclinical·NCT05766124·30 enrolled